Biocon Meets $650m Equity Infusion In Biocon Biologics To Fund Viatris Buy

Parent Company Invests Another $270m In Biocon Biologics After Earlier Allotment

 
• By Dean Rudge
  
Financing
Viatris will receive cash and equity for its biosimilars • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products